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We investigate the mechanism of talc pleurodesis (TP) in 20 patients with recurrent malignant pleural eﬀusion and 10 patients
with nonmalignant pleural eﬀusions. We measured IL-8 levels before and 6h after TP and ﬁnd a signiﬁcant threefold increase
(2.26ng/mL ± 0.7 to 6.5ng/mL 0.1), which explains the recruitment of inﬂammatory cells in these patients. We hypothesize that
TP is enable by stimulating the mesothelial cells (MS) to secrete FGF. A signiﬁcant tenfold increase in FGF-b (0.05ng/mL ± 0.02
to 0.44ng/mL 0.6) was seen 24h after talc instillation (P<0.04). In order to examine whether FGF-b is secreted by MS cells,
MS recovered from CHF patients with recurrent pleural eﬀusions were cultured for 48h in the presence or absence of increasing
concentrations of talc (from 100ng/mL to 1mg/mL). They produced signiﬁcant levels of FGF-b in a dose dependent manner
(P<0.005). We hypothesized that a successful pleurodesis involves an early enhanced recruitment of inﬂammatory cells through a
rise of IL-8 followed by enrollment of ﬁbroblasts from the submesothelial space through increased mesothelial FGF-b production.
1.Introduction
Recurrent pleural eﬀusion in cancer patients is a common
problemthatsigniﬁcantlyaﬀectstheirqualityoflives.Several
palliative treatment options are available for malignant
recurrent pleural eﬀusion in cancer patients who are not
responding to chemotherapy, repeated thoracocentesis, or
chemical pleurodesis. The most widely used pleurodesis
technique is based on the instillation of sclerosing agents
into the pleural space. The therapeutic goal in the man-
agement of symptomatic patients with malignant pleural
eﬀusions is to achieve eﬀective pleural sclerosis. The aim
of the sclerosant agent is to irritate both pleurae and to
induce mesothelial cell sloughing and subsequent formation
of adhesions between the parietal and visceral surfaces.
Although the agent must have irritant attributes, it needs to
limit and even obviate adverse eﬀects to the patient. Several
sclerosing agents are used in clinical practice, among them
doxycycline, minocycline, tetracycline, bleomycin, cisplatin,
etoposide, ﬂuorouracil, interferon-β, and corynebacterium
parvum. Talc has minimal long-term adverse side eﬀects and
it was shown to be the most eﬀective agent for preventing
recurrences [1]. The mechanisms of pleurodesis have not
yet been entirely understood. Diﬀuse pleural inﬂammation
and ﬁbrin deposition have been considered inﬂuential in the
successofpleuralsymphysis[2].Inanimalstudies,histologic
analysis of talc-treated pleurae [2] showed neutrophilic
predominance at 24h, followed by mononuclear inﬁltration
into the subpleural connective tissue matrix and peripheral
airspace of the lung. At day 7, the mononuclear inﬁltrate
was accompanied by ﬁbroblasts and collagen. Rodriguez-
Panadero et al. [3]showedasigniﬁcantincreaseofneutrophil
count in the pleural ﬂuid from patients whose pleurodesis
treatment was successful. Is not clear how the presence of
increased neutrophils in the pleural space contributes to
the success of pleural symphysis, but it does indicate that
the ﬁrst step of neutrophilic recruitment is critical. The
arrival of inﬂammatory phagocytic cells is mediated via the
release of chemotactic cytokines by activated mesothelial
cells [4]. Indeed, the ability of mesothelial cells to release2 Pulmonary Medicine
chemokines following stimulation by LPS, IL-1, or TNF-α
has been reported [4]. Pleural eﬀusions secondary to var-
ious diseases are associated with the presence of diﬀerent
inﬂammatory cells, but the formation of pleural adhesion is
slow compared to adhesion following the instillation of talc
and other sclerosing agents. Tetracycline, which was widely
used in the past as a sclerosing agent, increases IL-8 and
neutrophil predominance and release of growth-factor-like
activityforﬁbroblasts[5,6].Thedepositionofeﬃcientﬁbrin
within the pleural space in malignant eﬀusions to induce
pleurodesis is scanty. In contrast, eﬀusions induced by injury
and inﬂammation the deposition of ﬁbrin has been often
demonstrated [7–10]. It was postulated by Kuwahara et al.
that the pathogenesis for pleural ﬁbrosis after pleural injury
is through ﬁbroblast recruitment to the pleural damage sites
by mesothelial cells [11]. Those researchers used ﬁbronectin
as the chemotaxin and they showed a progressive time-
dependent increase in ﬁbroblast chemoattractant activity
by pleural mesothelial cell throughout 96h cultures. This
secretion of a mesothelial cell-derived ﬁbroblast chemoat-
tractant may play a role in the response of the pleurae
to injury and in the pathogenesis of pleural ﬁbrosis [11].
Fibroblast ﬁbrinopeptides during ﬁbrin formation stimulate
local mesothelial regeneration and proliferation as shown by
Griﬃth et al. [12]. Fibrin and collagen deposition in the
pleural connective tissue and in intrapleural adhesions was
reported by Hurewitz et al. after instillation of tetracycline
and doxycycline for pleurodesis [13]. They showed also
that ﬁbroblasts were the predominant inﬂammatory cells at
autopsies after 2 weeks of successful pleurodesis in rabbits.
Enhanced proliferation of ﬁbroblasts following asbestos
exposure [14] and tetracycline [15] have also been reported.
The mechanisms of talc pleurodesis have yet to be
delineated, raising a number of unanswered questions. Is the
role of talc in the pleurodesis process limited to an irritant
(foreign body) eﬀect that solely induces inﬂammation or
does it have a direct eﬀect on mesothelial and ﬁbroblasts
cells? Is the activation of mesothelial cells by the inﬂam-
matory process critical to the recruitment and proliferation
of ﬁbroblasts, and are the mesothelial cell responsible for
ﬁbroblast proliferation? Do mesothelial cells from cancer
patientsreacttotalcthesamedegreeasmesothelialcellsfrom
normal subjects?
1.1. Clinical Relevance. During the evolution of the disease,
cancer patients suﬀer from recurrent pleural eﬀusion that
endangers their lives and signiﬁcantly reduces their quality
of life. They are in need of medical support and frequently
requireimmediatetreatment.Althoughtalcagepleurodesisis
eﬀective, it causes side eﬀects and morbidity. By understand-
ing the ﬁbrotic process produced by talc, we will be able to
prevent most of those side eﬀects and lower the risk of injury
to the already compromised health of these patients.
We hypothesized that successful induction of pleurodesis
involves a cascade mechanism in which there is early
enhanced recruitment of inﬂammatory cells to the pleural
space through secretion of chemokines (mainly IL-8). This
inﬂammatory “soup” allows enrollment and proliferation
of ﬁbroblasts from the submesothelial space to the plural
space by secretion of ﬁbroblast growth factor production by
the mesothelial cells. These steps are induced directly and
p r i m a r yb yt a l c .
2. Methods
2.1. Clinical Protocol
2.1.1. Study Population. 20 patients with recurrent malig-
nant pleural eﬀusions and 10 patients with nonmalignant
pleural eﬀusions. Patients are followed during their hospi-
talization for the talcage procedure and at the outpatient
pulmonaryandoncologyclinicsafterdischarge.ChestX-rays
are performed before and shortly after talcage, and before
discharge. Pulmonary function tests are also performed
before and after talcage. A clinical chart is used to track any
failure of pleurodesis induction.
2.1.2. Thoracocentesis. Diagnostic thoracocentesis is per-
formed under local anesthesia, using the Bard∗I-Cath intra-
venous placement unit (Bard Ltd., UK) No. 16 connected
through a three-way stopcock to a syringe.
2.1.3.PleuralFluidExamination. Fluidisexaminedroutinely
for cytology, levels of glucose, LDH, protein, cholesterol, and
cultures. Pleural ﬂuids from the diagnostic thoracocentesis
are collected immediately before talcage, and at 6h and
24h after Talcage and frozen at −70◦C until cytokine
measurement.
2.1.4. Talcage Slurry Procedure. Instillation of talc (slurry
procedure) via tube thoracostomy (Sherwood Medical, Ire-
land) is performed after full expansion of the lung. Two 2g
of certiﬁed USP asbestos-free talc (Biolabs, Israel) sterilized
at 150◦C is mixed in 100mL of normal saline solution under
sterile conditions, and instillation is performed through the
tube thoracostomy at bedside. The tube is clamped for 2h
and the patient undergoes rotational maneuvers. Drainage
monitoring and volumes are recorded until drainage falls
below150mL/24hatwhichpointthethoracostomytubecan
be extracted [16].
2.2. In Vitro Protocol
2.2.1. IL-1 Mediation. The following experiment is designed
to clarify whether IL-8 production is mediated by primary
IL-1 activation. Cells recovered from pleural thoracocentesis
are cultured for 24h in 1640 RPMI 10% FBS in the presence
or absence of IL-1 receptor antagonist (1μg/mL/106 cells)
and talc (1μg/mL/106 cells). Supernatants are collected for
IL-8 measurements.
2.2.2. Talc Studies. Normal mesothelial cells recovered by
thoracocentesis from patients with intractable congestive
heart failure are cultured at equal concentrations in 1640
RPMI 20% FBS until conﬂuence. Cell viability is tested by
trypan blue dye exclusion. Cytospin preparations of pleural
ﬂuid cells are performed by counting the cells before culture
by cytospins and reconstituting them at a concentrationPulmonary Medicine 3
of 7.5 × 10−5 mix-cell/mL in RPMI-20% FCS. They are
exposed to graded concentrations of talc in serum-free
medium at increasing concentrations from 100ng/mL to
1mg/mL for 24h in order to establish a dose-response curve.
Supernatants for measuring cytokines and growth factors are
collected after centrifugation to remove excess talc and cells.
2.2.3. Cytokine Measurement. IL-8 and human ﬁbroblast
growth factor levels are quantiﬁed by sandwich-type en-
zyme-linked immunoassays ELISA (R & D systems, USA).
For the IL-8 and hFGF ELISAs, ﬂat-bottomed 96-
well microtiter plates are coated with an excess murine
monoclonal antibody to either IL-8 or hFGF. The pleural
ﬂuids from the diagnostic thoracocentesis and supernatants
from the mesothelial cell culture medium stimulated by
serial dilutions of talc are then added. After incubating, any
unbound protein is removed by washing with phosphate-
buﬀered saline (PBS) and an enzyme-linked polyclonal
antibody speciﬁc to either IL-8 or hFGF is added. The
antibody binds the antigen that had been immobilized
during the ﬁrst incubation period. Substrate solution is
added to the wells after another washing with PBS,. The
presence of IL-8 or hFGF is quantiﬁed by comparing the
optical density (OD) of the samples with the standard curve.
2.3.StatisticalAnalysis. DatawereanalyzedwiththeSigmaS-
tat statistical software package (Apple Computer, Cupertino,
CA, USA) and expressed as mean ± SD. The diﬀerences
between the group means were analyzed by analysis of
variance (ANOVA), with use of the Student-Newman-Keuls
test. Data were considered statistically signiﬁcant at P<0.05.
Isolated pleural ﬂuid cells are characterized as pleural
mesothelial cells (PMCs). In general, approximately 500mL
of centrifuged transudative pleural ﬂuid yields 12 conﬂuent
3.5cm diameter Petri dishes of mesothelial cells within 5
to 12 days when cultured as described. The mesothelial
cells were positively stained for vimentin, cytokeratin, and
hyaluronic acid mucin [17]. Cell morphology was deﬁned by
phase-contrast microscopy as having a cobblestone pattern,
and numerous microvilli were noted on transmission elec-
tron microscopy. All cells were utilized at the second passage
in 3.5cm diameter Petri dishes.
3. Results
3.1. IL-8 Production in Malignant Pleural Eﬀusion. We found
that pleural ﬂuid obtained from patients suﬀering from
recurrent malignant pleural eﬀusion had elevated IL-8 levels
(4.52ng/mL ± 4.4) compared to the pleural ﬂuid obtained
from noncancer patients suﬀering from nonmalignant, non-
infectious pleural eﬀusion (0.2ng/mL ± 0.4) (P<0.05)
(Figure 1).
3.2. Talc Stimulates IL-8 Secretion at Early Steps of the
Pleurodesis Process. The IL-8 levels in malignant pleural
eﬀusion showed an early (6h) signiﬁcant threefold increase
due to talc instillation (2.26ng/mL ± 0 . 7t o6 . 5n g / m L0 . 1 ) .
(Figure 2).
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Figure 1: IL-8 concentrations from noncancer noninfectious
recurrent pleural eﬀusion compared to malignant pleural eﬀusions.
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Figure 2: Pleural IL-8 concentrations before and after 6h from
talcage.
3.3. Talc Stimulates Conﬂuent Mesothelial Cells to Release C-
X-C Chemokine-IL-8. PMC cultures were stimulated with
varying doses of talc (2 to 64mg/cm2)f o r2 4 hi nt i s s u e
culture plates. Cell viability was documented by trypan blue
dye exclusion and vi-intensity character-visual inspection
with phase-contrast microscopy. Viable cells were expressed
as the percent viable cells of all cells. The PMC viability
decreased with increasing talc concentration. PMC viability
at a talc concentration of 64mg/cm2 was about 75%.
Cultured mesothelial cells released small amounts.
There was a signiﬁcant (P<0.04) tenfold increase in
FGF-blevels(0.05ng/mL ±0.02to0.44ng/mL0.6)24hafter
talc instillation (Figure 3).
Moreover, normal mesothelial cells were cultured in vitro
with talc in order to determine whether the mesothelial cells
are the ones responsible for the rise in FGF-b levels after
talcage: they produced signiﬁcant levels of FGF-b in a dose-
dependent manner (P<0.005) (Figure 4).
4. Discussion
In this work, we demonstrated cytokine IL-8 elevation in
early stages of talc pleurodesis compared to basic ﬁbroblast4 Pulmonary Medicine
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Figure 3: FGF-b production levels baseline and after talc instilla-
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Figure 4: Measurements of FGF-b production levels by Normal
mesothelial (MS) cells cultured in vitro in the presence of talc at
increasing concentrations.
growth factor (bFGF) increases in later phases. We also
showed that pleural mesothelial cells were either partially or
completely responsible for both IL-8 and bFGF elevation.
Current thinking of chemical pleurodesis [18–20] sug-
gests that an acute inﬂammatory reaction is initiated in
the pleural space following the administration of talc, with
an inﬂux of neutrophils and mononuclear cells associated
with an increase in interleukin-8 and other cytokines in
pleural ﬂuids. During the next step, pleural mesothelial cells
secrete signiﬁcant amounts of bFGF that stimulate ﬁbroblast
proliferation. The ﬁbroblasts synthesize collagen, resulting
in pleural adhesions between visceral and parietal pleurae,
and bFGF simultaneously promotes secretion of TGF-β and
VEGF that accentuates ﬁbrosis.
Our results demonstrate that pleural IL-8 levels from
patients with malignant pleural eﬀusion were higher com-
paredtoIL-8levelsinpatientswithnonmalignant,noninfec-
tious pleural eﬀusion (P<0.05). We also reported a three-
fold increase of IL-8 at 6 hours after talcage (P<0.005). A
number of investigations have shown that mesothelial cells
actively contribute to the acute inﬂammatory process in talc
pleurodesis. Genofre et al. [21] evaluated submicroscopic
features of active pleural remodeling associated with talc
pleurodesis and stated that talc acutely induces a prominent
injury to the mesothelial cells.
The mesothelial cells exposed to talc can actively produce
proinﬂammatory cytokines, such as IL-8 [18, 22], VEGF
[18], and bFGF [20]. Marchi et al. [19] demonstrated that
WBC, neutrophil percentage, and IL-8 levels were increased
in the ﬁrst 24h after talc exposure. Acencio et al. [23]
investigated the acute response of rabbit pleural mesothelial
cellschallengedwithtalc.Culturedrabbitpleuralmesothelial
cells were exposed to and assessed for the production of IL-
8, VEGF, and TGF-β. At 6h, the IL-8, VEGF, and TGF-β
levels produced by talc-exposed mesothelial cells increased
signiﬁcantly and remained elevated for up to 48h. The inves-
tigators concluded that pleural mesothelial cells may actively
mediate the primary inﬂammatory pleural response in talc-
induced pleurodesis injection, whereas VEGF and TGF-β1
levelswereinitiallylowerandincreasedwithtime.Therefore,
our results conﬁrm the data of other investigators on early
involvement of cytokine IL-8 in the talcage procedure that
induces recruitment of inﬂammatory cells in this process.
We hypothesized that a successful pleurodesis induction
involves an early enhanced recruitment of inﬂammatory
cells through a rise of pleural IL-8 concentrations followed
by enrollment of ﬁbroblasts from the submesothelial space
through increased mesothelial bFGF production. We found
a ten-fold increase of the bFGF level in pleural ﬂuid 24 hours
after talcage that conﬁrms the above hypothesis.
bFGF has been characterized as a key factor in successful
pleurodesis as well as in the formation of pleural eﬀusions. It
isamemberoftheFGFfamily.Thisgroupofmolecules,sim-
ilarly to the TGFβ superfamily, are pleiotropic regulators of
cellresponsesthatareinvolvedinadiverserangeofbiological
functions,includingproliferation,diﬀerentiationandwound
healing. Like TGFβ, bFGF has also been implicated in pleural
ﬁbrosis and can stimulate mesothelial cell proliferation in
vitro and in vivo.
We speculate that talc induces pleurodesis-ﬁbrosis by
direct stimulation of mesothelial cells to secrete bFGF. We
established mesothelial cell cultures from CHF patients with
recurrentpleuraleﬀusionsandincubatedthemwithdiﬀerent
concentrations of the talc. The cells produced signiﬁcant
levels of bFGF in a dose-dependent manner. These results
support data of Antony et al. [20] who showed that talc can
induce release of bFGF from mesothelial cells. Patients with
higher pleural ﬂuid bFGF levels after talc pleurodesis were
more likely to develop successful pleurodesis. An increase
in ﬁbroblast proliferation was stimulated by incubation in
pleural ﬂuid from these patients, which was reduced by
antibFGF antibodies. Antony et al. [20] demonstrated that
talcpleurodesisispartlydrivenbymesothelial-derivedbFGF.
Furthermore, those authors demonstrated that patients with
extensive pleural carcinomatosis and minimal intervening
normal mesothelium had signiﬁcantly lower quantities of
bFGF in their pleural ﬂuid compared to those with lim-
ited disease who subsequently developed successful pleuralPulmonary Medicine 5
symphysis. These ﬁndings suggested that mesothelium free
of tumor was necessary for successful pleurodesis [19]. A
recent study also showed that an intact pleural mesothe-
lium is critical in modulating the metastatic potential of
cancer cells within the pleural space. Malignant cells secrete
angiogenic factors that promote tumor growth, proliferation
of endothelial cells and invasion of surrounding tissue
by neovascularization. Talc-treated pleural mesothelium
counteracts these eﬀects by releasing endostatin, an anti-
angiogenic factor which may be responsible for tumor
containment within the pleural space and accounts for the
improved clinical outcome of patients with malignant pleu-
ral eﬀusions successfully pleurodesis with talc [24]. Lee et al.
[25] demonstrated that talc causes apoptosis of lung cancer
cells in a dose- and time-dependent manner. However, this
process is selective and spares the normal mesothelium.
The mechanism that determines pleural symphysis
involves the action of diﬀerent growth factors, such as
bFGFandTGF-β and,especially,vascularendothelialgrowth
f a c t o r( V E G F ) .R i b e i r oe ta l .[ 26] studied the acute eﬀects
of VEGF blockade on the expression of inﬂammatory
cytokines and pleural ﬂuid accumulation in rabbits that
received intrapleural injections of either talc or silver nitrate.
The animals pretreated with anti-VEGF antibody showed
signiﬁcant reductions in pleural ﬂuid volumes after talc or
silver nitrate injection. IL-8 levels, vascular permeability, and
macroscopic pleural adhesion scores were also reduced in
the groups that received bevacizumab. That study showed
that bevacizumab interferes in the acute phase of pleural
inﬂammationinducedbysilvernitrateortalc,reinforcingthe
role of VEGF as a key mediator in the production of pleural
eﬀusions.
Teixeira et al. [27] assessed the inﬂuence of the anti-
VEGF antibody (bevacizumab) on pleurodesis induced by
talc or silver in rabbits: antibody anti-VEGF interfered in
the pleurodesis induced by both agents, and the anti-VEGF
antibody inhibited adhesions between the pleural layers.
Collectively, our results provide experimental evidence
that cytokine IL-8 levels were elevated during the early
hours of pleural eﬀusion after talc instillation and that this
preceded the appearance of inﬂammatory cells in the pleural
cavity. Proﬁbrotic growth factor bFGF levels increased 24
hours after pleurodesis when ﬁbroblasts started to proliferate
in the pleura and produced collagen [19, 20], We also found
thatpleuralmesothelialcellssecretebothIL-8andbFGF.Our
present results closely agree with previous works of others
that showed interactions among resident and inﬂammatory
cells and cytokines and growth factors in the pathogenesis
of tissue ﬁbrosis during pleurodesis [18, 20, 22, 23]. These
interactions lead to excessive matrix production with ﬁbrosis
and scar formation in the pleural cavity. Although ﬁbroblasts
have been implicated as the eﬀector cells in pleural ﬁbrosis,
other resident cells, foremost among them, mesothelial cells,
may directly or indirectly play important roles as well.
Pleural injury and ﬁbrosis are characterized by excessive
ﬁbrin production. The pleural loculations evolve into ﬁbri-
nous adhesions under the inﬂuence of proﬁbrotic mediators,
such as bFGF and TGF-β, leading to the deposition of colla-
gen and the formation of adhesions between the visceral and
parietal surfaces. Elucidation of the speciﬁc steps involved in
inﬂammation and ﬁbrin turnover in pleural injury during
pleurodesis will lead to better understanding of this process
and to the development of novel sclerosants with potential
clinical applications.
At least two mechanistic pathways are likely to be
involved in talc-induced pleural ﬁbrosis: (i) the generation
of cytokines and inﬂammation and (ii) the production
of growth factors stimulating ﬁbroblast proliferation and
collagen synthesis. bFGF is considered to be the most potent
proﬁbrotic mediator, but the roles of other ﬁbrogenic medi-
ators need to be further studied as targets for pleurodesis.
Although the mechanisms involved in pleural ﬁbrosis are
unclear, recent evidence suggests that they may be associated
with the upregulation of genes for proﬁbrotic mediators,
such as bFGF and TGF-β [28]. However, further studies
are required to establish a molecular mechanism in the
development of pleural ﬁbrosis.
In summary, talc pleurodesis is the consequence of
sclerosant instillation and can manifest itself as diﬀuse
pleural thickening and ﬁbrosis. Although its pathogenesis
is not completely known, it is likely that the complex
interactions between resident and inﬂammatory cells and
proﬁbrotic mediators are integral to the development of
pleural ﬁbrosis. It is generally accepted that the primary
target cells for pleural ﬁbrosis are subpleural ﬁbroblasts,
however, our results as well as those of other studies
suggest that mesothelial cells may also play a signiﬁcant
role in the pathogenesis of this condition, both by initiating
inﬂammatory responses and producing proﬁbrotic growth
factors. A greater understanding of the biology of these
growth factors may allow therapeutic manipulation of these
cytokines to create pleurodesis and to stimulate pleural
adhesion/ﬁbrosis.
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